PirtobrUtinib as Frontline Therapy for Elderly Unfit/Frail Patient With MAntle Cell Lymphoma

NCT07207785 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

56

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Pirtobrutinib

Sponsor

Fondazione Italiana Linfomi - ETS